![]() (1) Based on the aggregate principal amount outstanding tendered at 5:00 p.m., New York City time, on for the Old 6.000% 2023 Notes and the Old 6.000% 2025 Notes, and 11:59 p.m., New York City time, on Jfor the Old 5.375% 2023 Notes (respectively, the "Early Tender Deadline"). $526.40 principal amount of New Unsecured Notes $344.44 principal amount of New Second Lien Notes $129.16 principal amount of New First Lien Notes $950.00 principal amount of New Unsecured Notes $456.86 principal amount of New Unsecured Notes $362.09 principal amount of New Second Lien Notes $181.05 principal amount of New First Lien Notes $201.13 principal amount of New Second Lien Notes $567.76 principal amount of New First Lien Notes The table below also sets forth the Total Consideration and Exchange Consideration that holders of the Old Notes will receive.ĭollars per $1,000 Principal Amount of Notes The aggregate principal amount of each series of Old Notes that were validly tendered and not validly withdrawn as of 11:59 p.m., New York City time, on J(the "Expiration Date"), as reported by the Exchange Agent and Information Agent, are specified in the table below. The complete terms and conditions of the Exchange Offers and Consent Solicitations, including the actual composition of the consideration each holder may receive, are more fully described in the Offering Memorandum and Consent Solicitation Statement, dated May 14, 2020, as supplemented on and J(as supplemented, the "Offering Memorandum and Consent Solicitation Statement"). $2,507,848,000 aggregate principal amount of 6.000% Senior Notes due 2028 co-issued by Endo DAC, Endo Finance and Endo Finco (the "New Unsecured Notes," and collectively with the New First Lien Notes and the New Second Lien Notes, the "New Notes"), and $947,220,000 aggregate principal amount of 9.500% Second Lien Senior Secured Notes due 2027 co–issued by Endo DAC, Endo Finance and Endo Finco (the "New Second Lien Notes," and together with the New First Lien Notes, the "New Secured Notes"), Plaintiff / appellant: Federal Trade Commissionĭefendant / appellee: Endo Pharmaceuticals Inc.ĭefendant / appellee: Endo International PLCĭefendant / appellee: Impax Laboratories, LLC, formerly known as IMPAX Laboratories, Inc.$516,000,000 aggregate principal amount of 7.500% Senior Secured Notes due 2027 issued by PPI (the "New First Lien Notes"), ![]() (Hegedus, Mark) Īccess additional case information on PACERĪccess the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. Hegedus and co-counsel Joel Marcus on behalf of Appellant FTC. LETTER sent regarding attorney membership to George G. LETTER sent regarding attorney membership to James Harris Weingarten for FTC. Appeal assigned USCA Case Number: 22-5137. District Court in 1:21-cv-00217-RCL filed by FTC. NOTICE OF APPEAL seeking review of a decision by the U.S. APPELLANT dispositive motions due directing party to file initial submissions: APPELLEE certificate as to parties due. APPELLANT deferred appendix statement due. ![]() STATEMENT OF INTENT REGARDING APPENDIX DEFERRAL filed by FTC Intent: AppxDeferred (Hegedus, Mark) ĬLERK'S ORDER filed directing party to file initial submissions: APPELLANT docketing statement due. (Hegedus, Mark) ĬERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES filed by FTC (Hegedus, Mark) JOINT UNOPPOSED MOTION to establish briefing schedule filed by FTC Length Certification: 70 words. (Hegedus, Mark) ĭOCKETING STATEMENT filed by FTC (Hegedus, Mark) Status of Transcripts: Final - No transcripts are needed for the appeal. UNDERLYING DECISION IN CASE submitted by FTC (Hegedus, Mark) (Lefkowitz, Jay) ĬERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES filed by Impax Laboratories, LLC and Amneal Pharmaceuticals, Inc (Lefkowitz, Jay) Hileman, Evelyn Blacklock on behalf of Appellees Amneal Pharmaceuticals, Inc and Impax Laboratories, LLC. ![]() Lefkowitz and co-counsel Devora Whitman Allon, Kevin M. STATEMENT OF ISSUES filed by FTC (Hegedus, Mark) ĮNTRY OF APPEARANCE filed by Jay P. (Gordon, George) ĬLERK'S ORDER filed considering the joint motion to establish briefing schedule, setting briefing schedule: APPELLANT Brief due. (Gordon, George) ĬERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES lodged by Endo International PLC - (Gordon, George) ĮNTRY OF APPEARANCE lodged by George Gordon and co-counsel Michael McGinley and Julia Chapman on behalf of Appellees Endo International PLC and Endo Pharmaceuticals Inc. UNOPPOSED MOTION to File Out of Time filed by Endo Pharmaceuticals Inc. UNOPPOSED MOTION to File Out of Time filed by Endo International PLC Length Certification: 101 Words. A more recent docket listingĬERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES lodged by Endo Pharmaceuticals Inc. This docket was last retrieved on July 20, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |